Harmony Biosciences/$HRMY
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Primary listing
Employees
268
Headquarters
Website
HRMY Metrics
BasicAdvanced
$2.3B
12.40
$3.17
0.82
-
Price and volume
Market cap
$2.3B
Beta
0.82
52-week high
$40.93
52-week low
$25.52
Average daily volume
863K
Financial strength
Current ratio
3.755
Quick ratio
3.461
Long term debt to equity
17.831
Total debt to equity
20.324
Interest coverage (TTM)
14.74%
Profitability
EBITDA (TTM)
249.51
Gross margin (TTM)
77.70%
Net profit margin (TTM)
22.48%
Operating margin (TTM)
27.32%
Effective tax rate (TTM)
19.43%
Revenue per employee (TTM)
$3,080,000
Management effectiveness
Return on assets (TTM)
13.20%
Return on equity (TTM)
25.93%
Valuation
Price to earnings (TTM)
12.397
Price to revenue (TTM)
2.735
Price to book
2.71
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
8.041
Free cash flow yield (TTM)
12.44%
Free cash flow per share (TTM)
4.884
Growth
Revenue change (TTM)
21.13%
Earnings per share change (TTM)
50.44%
3-year revenue growth (CAGR)
27.26%
3-year earnings per share growth (CAGR)
7.43%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
HRMY News
AllArticlesVideos
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
Business Wire·3 days ago
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
Business Wire·1 week ago
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
Business Wire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $2.3B as of December 11, 2025.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 12.4 as of December 11, 2025.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of December 11, 2025.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.